Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.

Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH.

Nefrologia. 2013;33(5):727-31. doi: 10.3265/Nefrologia.pre2013.Jun.12085.

2.

CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.

Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH.

Pediatr Nephrol. 2014 Aug;29(8):1363-71. doi: 10.1007/s00467-013-2679-1. Epub 2013 Nov 22.

3.

Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.

Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A.

Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.

PMID:
24429405
4.

Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.

Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH.

BMC Med. 2014 May 20;12:81. doi: 10.1186/1741-7015-12-81.

5.

Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.

Harita Y, Ishizuka K, Tanego A, Sugawara N, Chikamoto H, Akioka Y, Tsurumi H, Miura K, Gotoh Y, Tsujita M, Yamamoto T, Horike K, Takeda A, Oka A, Igarashi T, Hattori M.

Pediatr Nephrol. 2014 Sep;29(9):1553-60. doi: 10.1007/s00467-014-2808-5. Epub 2014 Apr 6.

PMID:
24705794
6.

Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.

Jin J, Li YW, He Q.

Transplant Proc. 2015 Jul-Aug;47(6):1760-5. doi: 10.1016/j.transproceed.2015.03.048.

PMID:
26293047
7.

Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin.

Bertelli R, Ginevri F, Caridi G, Dagnino M, Sandrini S, Di Duca M, Emma F, Sanna-Cherchi S, Scolari F, Neri TM, Murer L, Massella L, Basile G, Rizzoni G, Perfumo F, Ghiggeri GM.

Am J Kidney Dis. 2003 Jun;41(6):1314-21.

PMID:
12776285
8.

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.

Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H.

Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.

9.

Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.

Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ.

Kidney Int. 2010 Aug;78(3):296-302. doi: 10.1038/ki.2010.143. Epub 2010 May 19.

10.

Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome.

Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, Musante L, Candiano G, Perfumo F, Ghiggeri GM.

J Am Soc Nephrol. 2002 Jul;13(7):1946-52.

11.

[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Salcedo MT.

Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272. Spanish.

12.

Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?

Schlöndorff D.

Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.

PMID:
24583981
13.

Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.

Agrawal V, Prasad N, Jain M, Pandey R.

Clin Exp Nephrol. 2013 Dec;17(6):811-8. doi: 10.1007/s10157-013-0775-y. Epub 2013 Feb 2.

PMID:
23377573
14.

Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration.

Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason K, Scambler P.

Hum Mol Genet. 2002 Feb 15;11(4):379-88.

PMID:
11854170
15.

Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.

Li F, Zheng C, Zhong Y, Zeng C, Xu F, Yin R, Jiang Q, Zhou M, Liu Z.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.

16.

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Bock ME, Price HE, Gallon L, Langman CB.

Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.

17.

[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Agraz I, Salcedo MT.

Nefrologia. 2014;34(1):46-52. doi: 10.3265/Nefrologia.pre2013.Oct.12256. Spanish.

18.

Podocyte-associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis.

Laurin LP, Lu M, Mottl AK, Blyth ER, Poulton CJ, Weck KE.

Nephrol Dial Transplant. 2014 Nov;29(11):2062-9. doi: 10.1093/ndt/gft532. Epub 2014 Feb 4.

PMID:
24500309
19.

CD80 and suPAR: diagnostic and pathogenic value in minimal change disease and focal segmental glomerulosclerosis?

Davin JC.

Pediatr Nephrol. 2014 Aug;29(8):1465-6. doi: 10.1007/s00467-014-2777-8. Epub 2014 May 17. No abstract available.

PMID:
24839215
20.

mRNA sequencing of a novel NPHS2 intronic mutation in a child with focal and segmental glomerulosclerosis.

Benetti E, Caridi G, Centi S, Vella MD, Ghiggeri GM, Artifoni L, Murer L.

Saudi J Kidney Dis Transpl. 2014 Jul;25(4):854-7.

Supplemental Content

Support Center